 BURNABY, British Columbia, Oct. 03, 2021 GLOBE NEWSWIRE -- Xenon Pharmaceuticals Inc. Nasdaq:XENE, a neurology-focused biopharmaceutical company, today announced that Xenon management will host a conference call and webcast to discuss topline results from the XEN1101 Phase 2b X-TOLE clinical trial on Monday, October 4, 2021 at 7:30 am Eastern Time. 